Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LAKE is running hard and blowing through resistance nicely. With Obama speaking today at the NIH to push Congress to pass the $6.2 Billion to fight Ebola, this run could continue well into the remainder of the week.
Thanks in advance to those who are shorting this stock today or bailing out because of price drops. With Obama speaking today at the NIH asking Congress for Ebola funds and possible news in the near term on IBIO, I was able to scoop up 35K shares at an average price of $.91 per share.
Thank you, thank you, thank you.
5:05PM EST Today: Obama speech on Ebola
Watch Live here: http://www.whitehouse.gov/live/president-obama-delivers-remarks-national-institutes-health
5:05PM EST Today: Obama speech on Ebola
Watch Live here: http://www.whitehouse.gov/live/president-obama-delivers-remarks-national-institutes-health
Ebola Stocks on the Rise as Death Toll Hits 5,000
http://finance.yahoo.com/news/ebola-stocks-rise-death-toll-171800482.html
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / The death toll from the current Ebola outbreak has nearly hit 5,000 according to the World Health Organization (WHO). While the spread seems to be thankfully slowing, the Ebola stock phenomenon has now transitioned from fear-based speculative buying to concrete capital flows. Lakeland Industries (NASDAQ:LAKE), after surging on the mere news of Ebola and speculation that this would increase demand for the company's hazmat suits, is now surging again on the news that, indeed, the suits are starting to sell. Lakeland last week announced total orders of over one million Ebola suits from both government agencies and private sector customers. Sales will be accretive to earnings after January 31, 2015.
To give an idea of how fast this is going, Lakeland only first announced global availability of hazmat suits designed for Ebola on September 12th, less than two months ago.
Lakeland Competitor Alpha Pro Tech (NYSEMKT:APT) has yet to announce any large purchase orders for its suits in the wake of the torrent of Ebola news, but if and when an announcement is made, expect a large jump in Alpha's share price. The longer Ebola stays in the spotlight, the higher the chances that Alpha will soon take a slice of the pie, if it hasn't already done so pending an announcement.
That said, the latest developments on the epidemic are as follows:
1. A UN health worker with a confirmed case of Ebola has been flown to France for treatment.
2. A potential Ebola patient in North Carolina that developed a fever after returning from Liberia has preliminarily tested negative for the disease.
3. New York City Ebola patient improves, while a suspected case in Oregon is considered "low risk".
While Lakeland has already landed a major order with more likely to follow, newcomer Naturalnano (OTCMKTS:NNAN) has surprisingly also signed a purchase order with a California hospital, though the size of the order has not yet been disclosed. Naturalnano saw a volume spike to 107M shares traded from an average of 5M on the day it announced the order. Shares spiked over 300% in one day.
Hazmat suit companies are by no means the only stocks that should be monitored as Ebola developments continue to pepper the news. In fact, Big Pharma started turn its head on the issue back in August. On August 28, GlaxoSmithKline (NYSE:GSK) announced that it is developing an Ebola vaccine candidate together with the National Institutes of Health (NIH). The science of the vaccine is based on inserting an Ebola virus gene into a nonlethal vector virus, thereby having the immune system recognize Ebola genes without the threat of infection. Phase 1 trials began in mid-September and results are expected at the end of the year.
A successful Ebola vaccine could possibly see governments adopting it as mandatory in the West , considering the level of fear of the virus among the public. The fact that Glaxo is teaming up with the NIH on the treatment is a sign in that direction. We will know more with the publication of phase 1 results by the end of the year. Unlike the Hazmat suit companies above, Glaxo stock has not directly reacted to any Ebola news since the outbreak began in West Africa. Nevertheless, this vaccine warrants attention.
Glaxo, however, is not the only company developing an Ebola vaccine together with a Western government. Newlink Genetics (NASDAQ:NLNK), a midcap, is developing one with the Canadian government using a similar approach. Newlink is on a similar timeline to Glaxo on development of this vaccine, named VSV-EBOV. VSV-EBOV works by crossing Ebola genes with a virus that infects cattle but not humans. These viruses then express Ebola proteins, which would in theory prime the immune system to fight the real virus. A single injection of this vaccine was shown to provide complete immunity to Ebola in primates. Whether that translates to humans is the big question. In the meantime, Newlink is up 36% in one month.
Ironically, the Ebola vaccine that has been covered most extensively in the news, ZMAPP, is precisely the one that has yet to begin human testing according to the CDC. ZMAPP is a monoclonal antibody rather than a vaccine that provides active immunity. The drug itself attacks the virus directly instead of training the immune system to do so. Supplies of ZMAPP have been exhausted.
Perhaps even more strangely, there is an Ebola drug that has been approved, though not by the FDA. Avigan is an antiviral designed against the flu but seemingly effective against Ebola developed by Toyama Chemical in Japan and approved by Japanese regulators in March. Toyama Chemical is a subsidiary of Fujifilm (OTCMKTS:FUJIY).
So after all is said and done, there is in fact an approved treatment for Ebola, but it's in Japan.
It should be noted that since this epidemic began, no Americans have died of Ebola Virus Disease. In other words, the effective American survival rate of Ebola is 100% so far. Yet even so, orders for Hazmat suits and demand for more effective treatments will continue to rise along with Ebola stocks, so long as Ebola remains a meme on the news. And while the spread of Ebola seems to be ebbing off, hospitals and governments may still want to be prepared for the next outbreak should it occur. Meaning, vaccine development and hazmat suit purchases will most likely not cease when the current Ebola wave is finally over.
About Market Exclusive
Market Exclusive www.marketexclusive.com Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Pres Obama expects GOP to back ebola funding request. He speaks today at the National Institutes of Health.
http://thehill.com/policy/healthcare/overnights/225635-overnight-health-obama-expects-gop-to-back-ebola-funding-request
Nice find!
Ebola Stocks - High Alert:
OVERNIGHT HEALTH: White House expects GOP to deliver Ebola funds
http://thehill.com/policy/healthcare/overnights/225635-overnight-health-obama-expects-gop-to-back-ebola-funding-request
By Sarah Ferris - 12/01/14 06:40 PM EST
The White House is predicting that Republicans will back President Obama’s massive $6.2 billion funding request to keep Ebola out of the U.S. and stop its spread across West Africa.
“We’ve already seen expression of bipartisan support for this proposal, and I would expect that that bipartisan support will endure,” White House press secretary Josh Earnest told reporters.
Obama will again make his case for the funding request Tuesday at the National Institutes of Health, where leading scientists have made progress on an Ebola vaccine.
Earnest said the White House hopes the speech “will serve as an effective catalyst” for the funding as members of Congress look to complete next year's appropriations bill before Dec. 11. He added that “even top national security priorities ... need a little pushing and prodding to get through in timely fashion.”
But with lawmakers from both parties still picking apart the funding request, the $6 billion is still uncertain, House Appropriations Committee spokeswoman Jennifer Hing told The Hill. She added that it is “part of the scope of the negotiations on the Omnibus,” and no final decisions have been made.
House Foreign Affairs Committee Chairman Ed Royce (R-Calif.) has said he believes Congress would allocate the full amount, though at least one GOP member of the Senate Appropriations committee, Sen. John Boozman (R-Ark.), has said the request seemed too much.
Sen. Tom Carper (Del.), the Democratic chairman of the Senate Homeland Security Committee, also said last month that he still had questions about the funding. Read more here.
Monopolies under ObamaCare: Health insurance giants are eating up a bigger slice of the marketplace in most states, despite intense efforts under ObamaCare to increase competition.
The three largest insurance companies held an average of 86 percent of customers in the individual market last year, up from 83 percent in 2010, when the healthcare reform act was passed, according to a Monday report from the Government Accountability Office.
The marketplace remained highly concentrated from 2010-2013, showing the nation’s slow progress to dislodge long-standing insurance monopolies under the Affordable Care Act. Read more here.
An end to AIDS?: President Obama said Monday that the end of AIDS is “finally within reach” and could happen within his lifetime if the U.S. steps up its fight against the deadly disease.
“We’re closer than we’ve ever been to achieving the extraordinary: an AIDS-free generation,” Obama said in a video released Monday to mark World AIDS Day. “But we’ve got to keep fighting, all of us.”
In a speech at the White House, Secretary of State John Kerry also announced a major investment in training doctors and nurses to help treat and prevent AIDS, coupled with a commitment to double the number of children receiving life-saving treatments over the next two years in some of the worst-affected areas of Africa. Read more here.
Abortion rate at all-time low: The rate of abortions in the U.S. has reached “historic lows” after dropping by double-digits over the last decade, according to a new government report.
The number of women having abortions dropped 13 percent between 2002 and 2011, new data from the Centers for Disease Control and Prevention (CDC) show.
The report also shed light on the number of abortions performed after the politically charged timeframe of 20 weeks of gestation — just 1.4 percent of all abortions. The data indicates that very few women would be affected by the controversial GOP proposal to ban abortions after 20 weeks. Read more here.
Tuesday’s schedule:
President Obama will give remarks at the National Institutes of Health in Bethesda, touting the progress of a potential Ebola vaccine, and make the case for his $6.2 billion funding request.
Health and Human Services Secretary Sylvia Mathews Burwell will announce new data on the quality of healthcare at a CMS Healthcare Quality Conference in Baltimore. Later, Burwell will continue her nationwide campaign for open enrollment during a speech in Newark, N.J.
The American Academy of Family Physicians, the American Heart Association and other groups will hold a press conference calling for the confirmation of Dr. Vivek Murthy as surgeon general.
An advisory panel for the Food and Drug Administration will meet in Silver Spring to reconsider the ban on blood donations from gay men.
Doing well Gary. Thanks for asking. I have been ramping up on my education and have executed 3 nice trades totaling $4500 over the last 2-3 weeks. I am learning to be patient and wait for the set ups instead of chasing.
Thanks for confirming the info about Futures. I will begin reviewing that info tonight.
I like this board. The iBox has a good amount of info to get me started with commodities and options. Thanks.
Question. What should one check before the market opens to get an idea of where stocks or sectors may be headed? For example, today, gold and other precious metals are running but other sectors are tanking.
What can I reference to for an idea of where the market may be heading before it opens?
EDIT: Nevermind. Investopedia.com is my friend:
http://www.investopedia.com/search/default.aspx?q=How%20do%20Futures%20work
Better to live to fight another day. I am on the sidelines today...didn't scoop up any gold tickers so just using the day to scan for set-ups.
It sure is....Red Monday. Yowsers. With earnings coming out Dec 10th, the market may offer a good entry today.
The only place it is not a majority red is Gold and Silver. Gold and Silver stocks are surging today.
I would not hold my breath. R/S, dilute, repeat is the name of the game. SEC don't have the time to mess with OTC companies.
I went into trading "detox" to get the OTC investing / trading drug out of my system. Now I trade mainly big boards (only OTC I touch are FNMA and FMCC) and life and profits are good.
I wouldn't bet on the SEC saving the day here. You may be better off moving on. Good luck.
Ticker Board
ABPI (OTC)
AEMD (OTC)
AHPI (Major)
APT (Major)
BCRX (Major)
CBMC (OTC)
CEMI (Major)
CERS (Major)
CMRX (Major)
CONX (OTC)
GBIM (Major)
GNBT (OTC)
GOVX (OTC)
GSK (Major)
GWPC (OTC)
HEB (Major)
IBIO (Major)
IDNG (OTC)
INO (Major)
ITEN (OTC)
LAKE (Major)
NLNK (Major)
NNVC (Major)
NSEH (OTC)
NSPH (Major)
OBCI (Major)
PSID (OTC)
PURE (OTC)
RMCP (OTC)
SHMN (OTC)
SHPHF (OTC)
SIGA (Major)
SIMH (OTC)
SRPT (Major)
TKMR (Major)
VICL (Major)
VSR (Major)
WGBS (Major)
This was supposed to be a StockCharts chart but I cannot get it to link.
Iconiclassic, just want to say 'thanks' for posting these Gapper and Tanker lists. I am getting some good trading setups from them.
I second that.
SEC is so understaffed, it's ridiculous. You have a better chance of hitting big plays on big board stocks than seeing the SEC bust OTC scam stocks. Now, it does happen occasionally but I would not rest my hopes on it.
SEC issues warnings to people about investing in OTC stocks. That's about the best you are going to get from them the majority of the time. You are pretty much on your own from there.
I love shorts. They help us out big time when the Bulls decide playtime is over and run a ticker up. Massive covering by the shorts + bullish momentum = profits.
Bounce opportunities are coming. Woo hoo!
Come back to papa, ANV.
Please update the list to differentiate the big board stocks from the OTC stocks. It would help those who only do big boards or OTCs to quickly zero in on their desired plays.
Thanks man.
Don't be so hard on yourself, man. Most traders get sucked into OTC land. I have seen that it means Occupied by Thieves and Conmen.
Dust yourself off, tighten up on your trading, etc and come on over to the big boards. While the big boards are far from perfect, they offer much better opportunities to make money.
I use to play EWSI a year or so ago and gained and lost a lot. Ever since learning (and continually improving) how to effectively trade and perform Technical Analysis, I haven't looked back at the OTC except for FNMA or FMCC. Life's good on the Big Boards.
Technicals point to this one being pretty beat up. However, I like stocks like this....buy when everyone else exits the door. We all know oil and gold will come back but right now, people are running from them.
Let the shorts set us up for a nice payday in the not-too-distant future.
11/26/14: News Out
http://finance.yahoo.com/news/allied-nevada-optimizes-phase-1-133000602.html
Allied Nevada Optimizes Phase 1 of the Hycroft Mill Expansion with Improved Upfront Capital Requirements
I have learned to leave OTC stocks alone (FNMA and FMCC are the only exceptions). I have lost way more money playing them than I have gained.
Not much on the OTC besides "companies" that are in the business of selling shares and diluting to death. I like to trade liquid big boards only....I sleep better knowing my money can be pulled out with a stop loss or profits can be taken with Conditional Orders.
$VEEV was a good AH play for me yesterday. I was up $400 during regular trading hours.
Due to a great AH earnings report, my $400 gains from regular hours quickly shot up to a $2500 profit AH. I took the money and bailed.
This looks like a good Risk versus Reward setup.
Wooo Doggie! This puppy is running. Earnings coming out soon and they will probably be sweet!
...seems to be pointing to that confirmation that I was looking for:
“We succeeded in finding a structure that allows the trust to gain control of the company without shareholder votes,” John Brandow, an outside lawyer for the Federal Reserve Bank of New York, wrote in a document that an attorney for Greenberg’s Starr International Co. presented on the last day of witness testimony in the Washington trial over the terms of the rescue.
Pretty cool. Thanks!
Interesting that the former $2.47 battle field is thin right now. It could be a bear set up so once bulls push back to $2.49 area, they can crush them back down again.
Not quite trusting the thinning right now. Still watching.
Bears are clawing hard and it's early.
eTrade has it at $2.49.
Good for you. Good luck.
Good post.
Isn't a decision in the Starr vs USG not until sometime next year?
Agree.